Axial Improvement after Casirivimab/Imdevimab Treatment for COVID-19 in Parkinson's Disease

Can J Neurol Sci. 2023 Sep;50(5):777-778. doi: 10.1017/cjn.2022.269. Epub 2022 Jun 29.

¹ Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
² Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena and Reggio Emilia, Italy.
³ IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy.
⁴ Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Neuroscience Section, University of Catania, Catania, Italy.

No abstract available

Keywords: COVID-19; Coronavirus; Monoclonal antibodies; Parkinson’s disease; SARS-CoV-2.

Publication types